The real-world effectiveness of intravenous brivaracetam as a second-line treatment in status epilepticus
Epilepsy & Behavior · 2023-11 · 148 · 109464
DOI: 10.1016/j.yebeh.2023.109464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2023-11. Verfasst von Chiara Martellino und 14 weiteren Autor:innen. Beteiligte Einrichtung: Neurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Anticonvulsants, Status Epilepticus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Angelini Pharma.
Abstract (Originalsprache)
PURPOSE: Status epilepticus (SE) is defined by abnormally prolonged seizures that may lead to brain damage and death. Our aim was to evaluate the efficacy and tolerability (effectiveness) of intravenous brivaracetam (BRV) as a second-line treatment. METHODS: Twenty-one patients (median age 68 years ± 17.28) were prospectively recruited between June 2019 and December 2022. Patients were treated with BRV (50-200 mg) as a second-line add-on therapy for SE. We evaluated the response of SE to the administration of BRV in terms of SE termination and recurrence of epileptic seizures at 6, 12, and 24 h, also monitoring safety. The first-line therapy was represented by intravenous benzodiazepines (mainly diazepam). RESULTS: Almost a quarter of patients had generalized seizures, whereas the vast majority (76.2%) presented focal seizures. In 52.4% of patients, the underlying cause was cerebrovascular. Fourteen (66.7%) patients displayed a good early response in the subsequent 6 h. At 12 and 24 h, 8 (38%) and 11 (52.4%) patients, respectively, did not present seizures. CONCLUSION: The present study highlights the potential of BRV when used as an early add-on therapy in SE, further confirming its good safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
- Neurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy; Regional Epilepsy Center, University of Messina, Messina, Italy.
- National Research Council (CNR), Institute of Clinical Physiology (IFC), Clinical Epidemiology of Renal Diseases and Hypertension, Ospedali Riuniti, Reggio Calabria, Italy.
- Science of Health Department, University Magna Grecia of Catanzaro, Catanzaro, Italy.
- Neuroradiology Unit, University of Messina, Messina, Italy.
- Internal Medicine Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Förderung
- Angelini Pharma
Zitieren
APA
Martellino, C., Laganà, A., Atanasio, G., Lamanna, F., Attardo, S., Cascino, S., De Luca, M., Pardeo, O., Giacobbe, G., Tripepi, G., Roberti, R., Granata, F., Morace, C., Russo, E., & Labate, A. (2023). The real-world effectiveness of intravenous brivaracetam as a second-line treatment in status epilepticus. Epilepsy & Behavior, 148, 109464. https://doi.org/10.1016/j.yebeh.2023.109464
Vancouver
Martellino C, Laganà A, Atanasio G, Lamanna F, Attardo S, Cascino S, et al. The real-world effectiveness of intravenous brivaracetam as a second-line treatment in status epilepticus. Epilepsy & Behavior. 2023;148:109464. doi:10.1016/j.yebeh.2023.109464
BibTeX
@article{Martellino2023,
author = {Martellino, Chiara and Laganà, Angelina and Atanasio, Giorgia and Lamanna, Fabio and Attardo, Silvia and Cascino, Simona and De Luca, Marcella and Pardeo, Orazio and Giacobbe, Giuseppa and Tripepi, Giovanni and Roberti, Roberta and Granata, Francesca and Morace, Carmela and Russo, Emilio and Labate, Angelo},
title = {The real-world effectiveness of intravenous brivaracetam as a second-line treatment in status epilepticus},
journal = {Epilepsy & Behavior},
year = {2023},
volume = {148},
pages = {109464},
doi = {10.1016/j.yebeh.2023.109464}
}
EUVIMED